Pfizer two-shot course has 23% efficacy vs. Omicron in S. African study
Bloomberg reports: A two-shot course of Pfizer Inc.’s vaccine has just 22.5% efficacy against symptomatic infection with the omicron variant, but can thwart severe disease, according to laboratory experiments in South Africa. Researchers at the Africa Health Research Institute in Durban issued additional data on a small study released earlier this week. The research considered blood plasma samples from 12 participants. Scientists found omicron resulted in about a 41-fold reduction in levels of neutralizing antibodies produced by people who had…